临床肝胆病杂志2025，Vol.41Issue(11)：2248-2251,4.DOI:10.12449/JCH251108
《2025年美国肝病学会实践声明:儿童代谢相关脂肪性肝病的评估和管理》摘译
An excerpt of AASLD practice statement on the evaluation and management of metabolic dysfunction-associated steatotic liver disease in children
LIU Jiacheng 1RAO Huiying1
作者信息
- 1. Peking University People's Hospital,Peking University Hepatology Institute,Beijing 100044,China
- 折叠
摘要
Abstract
In March 2025,the American Association for the Study of Liver Diseases published its latest practice statement on metabolic dysfunction-associated steatotic liver disease(MASLD)in children.Compared with previous guidelines,this statement adopts the latest nomenclature and diagnostic criteria for MASLD,emphasizes hepatic steatosis in the presence of at least one cardiovascular metabolic risk factor,and elaborates on the unique epidemiological characteristics,pathophysiological patterns,and natural history of pediatric MASLD.Based on evidence-based medicine,the statement provides comprehensive guidance on the screening,diagnosis,treatment and monitoring of MASLD in children and emphasizes that lifestyle interventions form the cornerstone of treatment,and at present,there are still no drugs approved for the treatment of MASLD in children.This article gives an excerpt of the key recommendations in the practice statement.关键词
代谢相关脂肪性肝病/儿童/美国/诊疗准则Key words
Metabolic Dysfunction-Associated Steatotic Liver Disease/Child/United States/Practice Guideline引用本文复制引用
LIU Jiacheng,RAO Huiying..《2025年美国肝病学会实践声明:儿童代谢相关脂肪性肝病的评估和管理》摘译[J].临床肝胆病杂志,2025,41(11):2248-2251,4.
